

FORM PTO-1449 (Modified)		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Docket No. 50623.168	Application No. 09/872,135		
Approved for use through 10/31/2002							
INFORMATION DISCLOSURE CITATION in an Application				Applicant Brandon J. Yoe et al.			
(Use several sheets if necessary)				Filing Date May 31, 2001		Group Art Unit 3736	
U.S. PATENT DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
CTN	A1	2,072,303	3/2/37	Herrmann et al.	128	335.5	
	A2	4,977,901	12/18/90	Ofstead	128	772	
	A3	5,328,471	7/12/94	Slepian	604	101	
	A4	5,464,650	11/7/95	Berg et al.	427	2.30	
	A5	5,578,073	11/26/96	Haimovich et al.	623	1	
	A6	5,605,696	2/25/97	Eury et al.	424	423	
	A7	5,628,730	5/13/97	Shapland et al.	604	21	
	A8	5,667,767	9/16/97	Greff et al.	424	9.411	
	A9	5,670,558	9/23/97	Onishi et al.	523	9.412	
	A10	5,700,286	12/23/97	Tartaglia et al.	623	9.411	
	A11	5,716,981	2/10/98	Hunter et al.	514	449	
	A12	5,800,392	9/1/98	Racchini	604	9.411	
	A13	5,824,049	10/20/98	Ragheb et al.	623	1	
	A14	5,830,178	11/3/98	Jones et al.	604	49	
	A15	5,837,313	11/17/98	Ding et al.	427	2.21	
	A16	5,851,508	12/22/98	Greff et al.	424	9.411	
	A17	5,865,814	2/2/99	Tuch	604	265	
	A18	5,873,904	2/23/99	Ragheb et al.	623	1	
	A19	5,971,954	10/26/99	Conway et al.	604	96	
	A20	5,980,928	11/9/99	Terry	424	427	
	A21	5,980,972	11/9/99	Ding	427	2.24	
	A22	6,010,530	1/4/00	Goicoechea	623	1	
	A23	6,015,541	1/18/00	Greff et al.	424	1.25	
	A24	6,096,070	8/1/00	Ragheb et al.	623	1	
EXAMINER CTN Nguyen				DATE CONSIDERED 8/4/03			
EXAMINER: Initial if references considered whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (Modified)		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Docket No. 50623.168		Application No. 09/872,135		
Approved for use through 10/31/2002								
INFORMATION DISCLOSURE CITATION in an Application				Applicant Brandon J. Yoe et al.				
(Use several sheets if necessary)				Filing Date May 31, 2001		Group Art Unit 3736		
U.S. PATENT DOCUMENTS								
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date If Appropriate	
CTN	A25	6,153,252	11/28/00	Hossainy et al.	427	2.3		
↓	A26	6,165,212	12/26/00	Dereume et al.	623	1.13		
FOREIGN PATENT DOCUMENTS								
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No
CTN	B1	EP 0665023	8/2/95	European	<div style="writing-mode: vertical-rl; transform: rotate(180deg);"> RECEIVED JUN 14 2002 10 37 AM MAIL ROOM </div>	<div style="writing-mode: vertical-rl; transform: rotate(180deg);"> JUN 14 2002 </div>		
	B2	EP 0970711	1/12/00	European				
	B3	WO91/12846	9/5/91	PCT				
	B4	WO97/45105	12/4/97	PCT				
	B5	WO99/63981	12/16/99	PCT				
	B6	WO00/12147	3/9/00	PCT				
	B7	WO00/64506	11/2/00	PCT				
	B8	WO01/01890	1/11/01	PCT				
↓	B9	WO01/45763	6/28/01	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)								
CTN	C1	Barath et al., <i>Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury</i> , JACC 13(2):252A (1989) (Abstract).						
	C2	Matsumaru et al., <i>Embolic Materials for Endovascular Treatment of Cerebral Lesions</i> , J. Biomater. Sci. Polymer Edn. 8(7):555-569 (1997).						
	C3	Miyazaki et al., <i>Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice</i> , Chem. Pharm. Bull. 33(6):2490-2498 (1985).						
	C4	Miyazawa et al., <i>Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat</i> , J. Cardiovasc. Pharmacol. 30(2):157-162 (1997).						
	C5	Ohsawa et al., <i>Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty</i> , Am. Heart J. 136(6):1081-1087 (Dec. 1998).						
	C6	Shigeno, <i>Prevention of Cerebrovascular Spasm by Bosentan, Novel Endothelin Receptor</i> , Chem. Abstracts 125:212307 (1996).						
↓	C7	van der Giessen et al., <i>"Edge Effect" of ³²P Radioactive Stents is Caused by the Combination of Chronic Stent Injury and Radioactive Dose Falloff</i> , Circ. 104:2236-2241 (Oct. 30, 2001).						
EXAMINER CT Nguyen				DATE CONSIDERED 8/4/03				
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								